⁹⁹Tc^m-MDP and ⁹⁹Tc^m-DPD in Pathologic Bone Lesions

Abstract

The efficiency of 99Tcm-methylene diphosphonate (MDP) and 99Tcm-dicarboxypropane diphosphonate (DPD) to detect pathologically increased bone uptake was evaluated both by computed quantitative intra-individual and visual inter-individual comparison. Twelve patients with altogether 44 metastases in ribs and lumbar vertebrae were evaluated quantitatively. The lesion to normal bone ratio (mean ± SD) was, with MDP, 2.9 ± 1.6 and with DPD 2.4 ± 1.2 (p<0.001), and the normal bone to soft tissue ratios with MDP 8.5 ± 5.0 and with DPD 9.4±6.1 (NS). Visual analysis of 162 patients with 334 focal lesions showed no significant difference between two MDP preparations and one DPD preparation. Visual and quantitative comparison in the three most common malignancies studied (breast, prostatic, and lung carcinoma) gave the same result. Because the lesion to normal bone ratios were high with both agents, and there was no significant difference on visual analysis, both radiopharmaceuticals are considered to be relevant bone seeking agents and the difference between MDP and DPD is only academic and not of practical value.

Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ)

“…If anatomical imaging should be added, hybrid SPECT/CT scanners are available. For detecting bony infections, technetium-99m methylene diphosphonate (99Tcm-MDP) or technetium-99 m-DPD (99Tcm-DPD) are frequently used nuclides; they show no significant differences in detecting “pathologically increased bone uptake” [ 47 ]. MRONJ should not show an uptake in the necrotic zone, but due to the associated infection, a nuclide uptake may be seen.…”

ROC study and SUV threshold using quantitative multi-modal SPECT for bone imaging

“…All five sites used standard dose or weight-based injected dose adaptation, according to their clinical practice. The targeted post-administration imaging time was 3 h. Since there is no known clinical difference between the two radiopharmaceuticals, we pooled the data (Lantto et al 1987 ).…”

“…Bone imaging with 99m Tc 2,3-dicarboxypropane-1,1-diphosphonate (DPD) or methylene diphosphonate (MDP) is one of the main pillars of nuclear medicine for oncology and orthopedic applications (Buell et al 1982 ; Lantto et al 1987 ). Single-photon emission computed tomography (SPECT) with these tracers has superior clinical performance to two-dimensional (2D) scintigraphy (Even-Sapir et al 2009 ).…”

18F- based Quantification of the Osteogenic Potential of hMSCs

“…As technetium is a gamma-radiation emitting radioactive source, the distribution of the tracer can be imaged three-dimensionally using single-photon emission computed tomography (SPECT). Downsides of this method are that it only allows low-resolution imaging and it has a lower sensitivity than other nuclear medicine methods [ 19 ]. Besides 99m Technetium, fluorine-18 ( 18 F) is one of the most common tracers used to target hydroxyapatite in modern nuclear medicine.…”